GlassScriptPhysician profile
Jorge M Chaves
NPI 1265610752
$26,819.08
in general payments reported to CMS, 2019-2025
65 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $9,365 · 2021: $6,385 · 2022: $1,303 · 2023: $6,901 · 2024: $980 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,830 · Food and Beverage: $3,152 · Travel and Lodging: $1,048 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,830.00 |
| Food and Beverage | $3,152.29 |
| Travel and Lodging | $1,048.37 |
| Education | $166.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $7,639.71 | 2020-2024 | Onivyde |
| Epizyme, INC. | $3,509.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $2,948.97 | 2020-2025 | Lynparza, Enhertu, Tagrisso |
| Janssen Biotech, INC. | $2,809.40 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Kite Pharma, INC. | $1,700.00 | 2021 | |
| Merck Sharp & Dohme LLC | $1,642.26 | 2019-2025 | Keytruda, Reblozyl, Welireg |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| G1 Therapeutics, INC. | $1,524.58 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $374.86 | 2019-2025 | Opdivo, Opdualag |
| Abbvie INC. | $372.17 | 2020-2025 | Venclexta |
| Incyte Corporation | $209.13 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Beigene USA, INC. | $158.31 | 2022-2025 | Tevimbra, Brukinsa |
| Daiichi Sankyo INC. | $152.11 | 2019-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $138.98 | 2020-2025 | Libtayo, Lynozyfic |
| Pfizer INC. | $133.81 | 2019-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $132.36 | 2021-2023 | Imbruvica, Epkinly |
| Taiho Oncology, INC. | $128.88 | 2023-2025 | |
| Astellas Pharma US INC | $122.79 | 2023-2025 | Padcev, Xtandi, Vyloy |
| Stemline Therapeutics INC. | $120.72 | 2024-2025 | Orserdu |
| Lilly USA, LLC | $105.49 | 2019-2025 | Jaypirca, Verzenio |
| Genentech USA, INC. | $104.40 | 2023-2025 | Columvi, Lunsumio, Tecentriq |
| Eisai INC. | $98.16 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.38 | 2019-2025 | Fruzaqla, Alunbrig |
| Genzyme Corporation | $79.38 | 2019-2025 | |
| Exelixis INC. | $78.05 | 2023-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $73.47 | 2019-2023 | |
| Celgene Corporation | $71.54 | 2019-2023 | Reblozyl |
| Agios Pharmaceuticals, INC. | $62.35 | 2019-2024 | |
| Emd Serono, INC. | $56.79 | 2023-2024 | Bavencio, Tepmetko |
| Deciphera Pharmaceuticals INC. | $50.19 | 2023-2024 | Qinlock |
| Beone Medicines USA, INC. | $45.34 | 2025 | Tevimbra, Brukinsa |
| Sanofi-Aventis U.S. LLC | $34.63 | 2019-2020 | |
| Gilead Sciences, INC. | $33.58 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $33.38 | 2025 | Jemperli |
| Seagen INC. | $30.05 | 2023 | Tukysa |
| Tempus Ai, INC | $29.96 | 2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $27.64 | 2023 | Rezlidhia, Tavalisse |
| Jazz Pharmaceuticals INC. | $27.05 | 2023 | |
| Aadi Bioscience, INC. | $23.91 | 2023 | Fyarro |
| Cti Biopharma Corp. | $23.21 | 2023 | Vonjo |
| Dova Pharmaceuticals | $23.00 | 2019 | |
| Melinta Therapeutics, LLC | $22.65 | 2019 | |
| Iovance Biotherapeutics, INC. | $21.36 | 2025 | Amtagvi |
| Syndax Pharmaceuticals, INC. | $21.19 | 2025 | |
| Kyowa Kirin, INC. | $21.02 | 2019 | |
| Mirati Therapeutics, INC. | $20.96 | 2023 | Krazati |
| Aurobindo Pharma USA, INC. | $17.82 | 2019 | |
| Tersera Therapeutics LLC | $17.55 | 2024 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $16.61 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $15.76 | 2020 | |
| Amgen INC. | $14.75 | 2019 | |
| Genmab U.S., INC. | $13.56 | 2024 | Epkinly |
| Pharmaessentia USA Corporation | $13.50 | 2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2019 | |
| Coherus Oncology, INC. | $13.00 | 2023 |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Chaves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.